

RESMED INC  
Form 10-Q  
February 02, 2012  
Table of Contents

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

**December 31, 2011 For the quarterly period ended December 31, 2011**

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from            to**

**Commission File Number: 001-15317**

**ResMed Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**

(State or other jurisdiction of incorporation or organization)

**98-0152841**

(I.R.S. Employer Identification No.)

**9001 Spectrum Center Blvd.**

**San Diego, CA 92123**

**United States of America**

(Address of principal executive offices)

**(858) 836-5000**

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer

Non-accelerated filer  (Do not check if a smaller reporting company) Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

At January 25, 2012, there were 144,184,956 shares of Common Stock (\$0.004 par value) outstanding. This number excludes 23,206,473 shares held by the registrant as treasury shares.

**Table of Contents**

**RESMED INC. AND SUBSIDIARIES**

**INDEX**

|                |  |    |
|----------------|--|----|
| <b>Part I</b>  | <b><u>Financial Information</u></b>  | 3  |
| Item 1         | <u>Financial Statements</u>  | 3  |
|                | <u>Condensed Consolidated Balance Sheets (Unaudited) as of December 31, 2011 and June 30, 2011</u>                           | 3  |
|                | <u>Condensed Consolidated Statements of Income (Unaudited) for the Three and Six Months Ended December 31, 2011 and 2010</u> | 4  |
|                | <u>Condensed Consolidated Statements of Cash Flows (Unaudited) for the Six Months Ended December 31, 2011 and 2010</u>       | 5  |
|                | <u>Notes to the Condensed Consolidated Financial Statements (Unaudited)</u>  | 6  |
| Item 2         | <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>                                 | 17 |
| Item 3         | <u>Quantitative and Qualitative Disclosures About Market Risk</u>  | 27 |
| Item 4         | <u>Controls and Procedures</u>   | 29 |
| <b>Part II</b> | <b><u>Other Information</u></b>  | 30 |
| Item 1         | <u>Legal Proceedings</u>   | 30 |
| Item 1A        | <u>Risk Factors</u>  | 30 |
| Item 2         | <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>   | 30 |
| Item 3         | <u>Defaults Upon Senior Securities</u>   | 30 |
| Item 4         | <u>Removed and Reserved</u>  | 30 |
| Item 5         | <u>Other Information</u>   | 30 |
| Item 6         | <u>Exhibits</u>  | 31 |
|                | <u>Signatures</u>  | 32 |

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 1

**Item 1. Financial Statements****RESMED INC. AND SUBSIDIARIES**

Condensed Consolidated Balance Sheets (Unaudited)

(In US\$ thousands, except share and per share data)

|  | December 31,<br>2011 | June 30,<br>2011    |
|--|----------------------|---------------------|
| <b>Assets</b>                                      |                      |                     |
| Current assets:                                    |                      |                     |
| Cash and cash equivalents                          | \$ 723,233           | \$ 735,267          |
| Accounts receivable, net                           | 238,764              | 274,352             |
| Inventories (note 5)                               | 184,420              | 200,777             |
| Deferred income taxes                              | 13,598               | 13,875              |
| Income taxes receivable                            | 2,097                | 9,294               |
| Prepaid expenses and other current assets          | 84,655               | 58,887              |
| <b>Total current assets</b>                        | <b>1,246,767</b>     | <b>1,292,452</b>    |
| Non-current assets:                                |                      |                     |
| Property, plant and equipment, net                 | 441,000              | 462,107             |
| Goodwill and other intangible assets, net (note 7) | 322,754              | 283,398             |
| Deferred income taxes                              | 17,405               | 18,922              |
| Other assets                                       | 13,552               | 12,043              |
| <b>Total non-current assets</b>                    | <b>794,711</b>       | <b>776,470</b>      |
| <b>Total assets</b>                                | <b>\$ 2,041,478</b>  | <b>\$ 2,068,922</b> |
| <b>Liabilities and Stockholders Equity</b>         |                      |                     |
| Current liabilities:                               |                      |                     |
| Accounts payable                                   | 45,763               | \$ 55,194           |
| Accrued expenses                                   | 112,286              | 103,787             |
| Deferred revenue                                   | 41,840               | 45,125              |
| Income taxes payable                               | 26,444               | 3,931               |
| Deferred income taxes                              | 574                  | 640                 |
| Current portion of long-term debt (note 8)         | 1,450                | 163                 |
| <b>Total current liabilities</b>                   | <b>228,357</b>       | <b>208,840</b>      |
| Non-current liabilities:                           |                      |                     |
| Deferred income taxes                              | 7,921                | 8,051               |
| Deferred revenue                                   | 15,755               | 17,237              |
| Long-term debt (note 8)                            | 225,000              | 100,000             |
| Income taxes payable                               | 3,370                | 4,057               |
| <b>Total non-current liabilities</b>               | <b>252,046</b>       | <b>129,345</b>      |
| <b>Total liabilities</b>                           | <b>480,403</b>       | <b>338,185</b>      |
| Commitments and contingencies (notes 14)           |                      |                     |

## Edgar Filing: RESMED INC - Form 10-Q

Stockholders' equity: (note 11)

|   |                     |                     |
|---|---------------------|---------------------|
| Preferred stock, \$0.01 par value, 2,000,000 shares authorized; none issued   | 0                   | 0                   |
| Common stock, \$0.004 par value, 350,000,000 shares authorized; 167,285,687 issued and 144,679,214 outstanding at December 31, 2011 and 165,783,516 issued and 151,668,786 outstanding at June 30, 2011 | 579                 | 607                 |
| Additional paid-in capital  | 834,179             | 798,461             |
| Retained earnings   | 1,225,252           | 1,111,862           |
| Treasury stock, at cost, 22,606,473 shares at December 31, 2011, and 14,114,730 shares at June 30, 2011   | (739,812)           | (504,625)           |
| Accumulated other comprehensive income (note 4)   | 240,877             | 324,432             |
| <b>Total stockholders' equity</b>   | <b>1,561,075</b>    | <b>1,730,737</b>    |
| <b>Total liabilities and stockholders' equity</b>   | <b>\$ 2,041,478</b> | <b>\$ 2,068,922</b> |

See the accompanying notes to the unaudited condensed consolidated financial statements.

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES**

## Condensed Consolidated Statements of Income (Unaudited)

(In US\$ thousands, except per share data)

|  | Three Months Ended<br>December 31, |            | Six Months Ended<br>December 31, |            |
|--|------------------------------------|------------|----------------------------------|------------|
|  | 2011                               | 2010       | 2011                             | 2010       |
| Net revenues                               | \$ 332,738                         | \$ 305,986 | \$ 647,513                       | \$ 587,998 |
| Cost of sales                              | 134,023                            | 119,987    | 263,743                          | 228,045    |
| Gross profit                               | 198,715                            | 185,999    | 383,770                          | 359,953    |
| Operating expenses:                        |                                    |            |                                  |            |
| Selling, general and administrative        | 100,552                            | 91,581     | 194,755                          | 176,371    |
| Research and development                   | 27,218                             | 21,972     | 53,424                           | 41,712     |
| Amortization of acquired intangible assets | 3,691                              | 2,573      | 7,462                            | 4,604      |
| Donation to Foundation                     | 0                                  | 0          | 0                                | 1,000      |
| Total operating expenses                   | 131,461                            | 116,126    | 255,641                          | 223,687    |
| Income from operations                     | 67,254                             | 69,873     | 128,129                          | 136,266    |
| Other income, net:                         |                                    |            |                                  |            |
| Interest income, net                       | 7,181                              | 6,005      | 14,103                           | 11,102     |
| Other, net                                 | 8,496                              | 3,043      | 7,196                            | 8,106      |
| Total other income, net                    | 15,677                             | 9,048      | 21,299                           | 19,208     |
| Income before income taxes                 | 82,931                             | 78,921     | 149,428                          | 155,474    |
| Income taxes                               | 20,059                             | 20,465     | 36,038                           | 40,310     |
| Net income                                 | \$ 62,872                          | \$ 58,456  | \$ 113,390                       | \$ 115,164 |
| Basic earnings per share                   | \$ 0.43                            | \$ 0.38    | \$ 0.76                          | \$ 0.76    |
| Diluted earnings per share (note 3)        | \$ 0.42                            | \$ 0.37    | \$ 0.75                          | \$ 0.73    |
| Basic shares outstanding                   | 146,369                            | 152,420    | 148,368                          | 152,006    |
| Diluted shares outstanding                 | 149,515                            | 157,593    | 151,835                          | 157,276    |

See the accompanying notes to the unaudited condensed consolidated financial statements.

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES**

## Condensed Consolidated Statements of Cash Flows (Unaudited)

(In US\$ thousands)

|  | Six Months Ended<br>December 31, |            |
|--|----------------------------------|------------|
|  | 2011                             | 2010       |
| <b>Cash flows from operating activities:</b>                                     |                                  |            |
| Net income   | \$ 113,390                       | \$ 115,164 |
| Adjustment to reconcile net income to net cash provided by operating activities: |                                  |            |
| Depreciation and amortization  | 43,404                           | 32,988     |
| Impairment of long-lived assets  | 0                                | 2,257      |
| Stock-based compensation costs   | 14,590                           | 16,503     |
| Impairment of cost-method investments  | 2,299                            | 0          |
| Foreign currency revaluation   | (9,504)                          | (12,292)   |
| Gain on previously held equity interest resulting from business combination      | (2,070)                          | 0          |
| Tax benefit from stock option exercises  | (1,796)                          | (8,550)    |
| Changes in operating assets and liabilities, net of effect of acquisitions:      |                                  |            |
| Accounts receivable, net   | 26,310                           | 1,720      |
| Inventories, net   | 8,936                            | (9,036)    |
| Prepaid expenses, net deferred income taxes and other current assets             | (21,566)                         | 3,479      |
| Accounts payable, accrued expenses and other liabilities                         | 26,163                           | (14,779)   |
| Net cash provided by operating activities  | 200,156                          | 127,454    |
| <b>Cash flows from investing activities:</b>                                     |                                  |            |
| Purchases of property, plant and equipment                                       | (25,189)                         | (33,119)   |
| Patent registration costs  | (3,781)                          | (3,609)    |
| Proceeds from sale of maturing investment securities                             | 0                                | 3,950      |
| Purchases of other intangible assets   | (7,000)                          | (1,130)    |
| Business acquisitions, net of cash acquired                                      | (51,923)                         | (21,150)   |
| Purchases of cost-method investments   | (4,796)                          | (1,166)    |
| Purchases of foreign currency options  | 0                                | (543)      |
| Proceeds from exercise of foreign currency options                               | 5,036                            | 9,989      |
| Net cash used in investing activities  | (87,653)                         | (46,778)   |
| <b>Cash flows from financing activities:</b>                                     |                                  |            |
| Proceeds from issuance of common stock, net                                      | 19,935                           | 53,742     |
| Tax benefit from stock option exercises  | 1,796                            | 8,550      |
| Purchases of treasury stock  | (235,971)                        | (41,361)   |
| Proceeds from borrowings   | 175,384                          | 0          |
| Repayment of borrowings  | (55,393)                         | (59,382)   |
| Net cash used in financing activities  | (94,249)                         | (38,451)   |
| Effect of exchange rate changes on cash  | (30,288)                         | 85,200     |
| Net increase (decrease) in cash and cash equivalents                             | (12,034)                         | 127,425    |

Edgar Filing: RESMED INC - Form 10-Q

|  |            |            |
|--|------------|------------|
| Cash and cash equivalents at beginning of period         | 735,267    | 488,776    |
| Cash and cash equivalents at end of period               | \$ 723,233 | \$ 616,201 |
| <b>Supplemental disclosure of cash flow information:</b> |            |            |
| Income taxes paid  | \$ 21,855  | \$ 43,554  |
| Interest paid  | \$ 1,792   | \$ 694     |
| Fair value of assets acquired, excluding cash            | \$ 24,648  | \$ 17,142  |
| Liabilities assumed                                      | (11,906)   | (450)      |
| Goodwill on acquisition                                  | 51,798     | 4,958      |
| Total purchase price                                     | 64,540     | 21,650     |
| Less: Consideration not paid in the current period       | (12,617)   | (500)      |
| Cash paid for acquisition                                | \$ 51,923  | \$ 21,150  |

See the accompanying notes to the unaudited condensed consolidated financial statements.



---

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES**

**Notes to the Condensed Consolidated Financial Statements**

**(Unaudited)**

**(1) Organization and Basis of Presentation**

References in these notes to the unaudited condensed consolidated financial statements to ResMed Inc. , we , us , our or the Company refer to ResMed Inc. and its consolidated subsidiaries.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ( U.S. GAAP ) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the U.S. Securities and Exchange Commission ( SEC ). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2012.

The condensed consolidated financial statements for the six months ended December 31, 2011 and 2010 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2011.

**(2) Recently Issued Accounting Pronouncements**

In September 2011, the Financial Accounting Standards Board ( FASB ) issued authoritative guidance intended to reduce the cost and complexity of the annual goodwill impairment test by providing entities an option to perform a qualitative assessment to determine whether further impairment testing is necessary. Under the amendments in this standard, an entity is not required to calculate the fair value of a reporting unit unless the entity determines that it is more likely than not that its fair value is less than its carrying amount. The amendments are effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011. Early adoption is permitted. We do not expect the adoption of this standard in fiscal year 2012, if we early adopt these amendments, or in fiscal year 2013, to have a material impact on our condensed consolidated financial statements.

In June 2011, the FASB issued authoritative guidance with respect to the presentation of other comprehensive income in financial statements. The main provisions of the standard provide that an entity that reports other comprehensive income has the option to present comprehensive income in either a single statement or in a two-statement approach. A single statement must present the components of net income and total net income, the components of other comprehensive income and total other comprehensive income, and a total for comprehensive income. In the two-statement approach, an entity must present the components of net income and total net income in the first statement, followed by a financial statement that presents the components of other comprehensive income, a total for other comprehensive income, and a total for comprehensive income. Early adoption is permitted. We do not expect the adoption of this standard in fiscal year 2012, if we early adopt these amendments, or in fiscal year 2013, to have a material impact on our condensed consolidated financial statements.

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)****(3) Earnings Per Share**

Basic earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options and restricted stock units.

Stock options of 1,985,962 and 683,000 for the three months ended December 31, 2011 and 2010, respectively, and stock options of 1,714,404 and 633,000 for the six months ended December 31, 2011 and 2010, were not included in the computation of diluted earnings per share as the effect of exercising these options would have been anti-dilutive.

Basic and diluted earnings per share for the three and six months ended December 31, 2011 and 2010 are calculated as follows (in thousands except per share data):

|  | Three Months Ended<br>December 31, |           | Six Months Ended<br>December 31, |            |
|--|------------------------------------|-----------|----------------------------------|------------|
|  | 2011                               | 2010      | 2011                             | 2010       |
| Numerator:   |                                    |           |                                  |            |
| Net income, used in calculating diluted earnings per share | \$ 62,872                          | \$ 58,456 | \$ 113,390                       | \$ 115,164 |
| Denominator:   |                                    |           |                                  |            |
| Basic weighted-average common shares outstanding           | 146,369                            | 152,420   | 148,368                          | 152,006    |
| Effect of dilutive securities:                             |                                    |           |                                  |            |
| Stock options and restricted stock units                   | 3,146                              | 5,173     | 3,467                            | 5,270      |
| Diluted weighted average shares                            | 149,515                            | 157,593   | 151,835                          | 157,276    |
| Basic earnings per share                                   | \$ 0.43                            | \$ 0.38   | \$ 0.76                          | \$ 0.76    |
| Diluted earnings per share                                 | \$ 0.42                            | \$ 0.37   | \$ 0.75                          | \$ 0.73    |

**(4) Comprehensive Income**

Accumulated other comprehensive income was comprised of foreign currency translation gains of \$240.9 million at December 31, 2011 and \$324.4 million at June 30, 2011.

We do not provide for U.S. income taxes on foreign currency translation adjustments since we do not provide for such taxes on undistributed earnings of foreign subsidiaries.

**(5) Inventories**

Inventories were comprised of the following at December 31, 2011 and June 30, 2011 (in thousands):

December 31, 2011

June 30, 2011

Edgar Filing: RESMED INC - Form 10-Q

|                  |    |         |    |         |
|------------------|----|---------|----|---------|
| Raw materials    | \$ | 74,942  | \$ | 73,836  |
| Work in progress |    | 2,601   |    | 4,147   |
| Finished goods   |    | 106,877 |    | 122,794 |
| Inventories, net | \$ | 184,420 | \$ | 200,777 |

- 7 -

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)****(6) Cost-Method Investments**

The aggregate carrying amount of our cost-method investments at December 31, 2011 and June 30, 2011, was \$4.5 million and \$4.3 million, respectively. During the six months ended December 31, 2011 we re-measured a previously held equity interest to its acquisition-date fair value as a result of acquiring the remaining interest as part of a business combination and recognized a gain of \$2.1 million in other income, net within our condensed consolidated statements of income. See Note 15 for additional information.

We periodically evaluate the carrying value of our cost-method investments, when events and circumstances indicate that the carrying amount of an asset may not be recovered. We determine the fair value of our cost-method investments to evaluate whether impairment losses shall be recorded using Level 3 inputs. These investments include our holdings in privately held service companies and research companies that are not exchange traded and therefore not supported with observable market prices. However, these investments are valued by reference to their net asset values which can be market supported and unobservable inputs including future cash flows. During the six months ended December 31, 2011 and 2010, we recognized \$2.3 million and \$nil, respectively, of impairment losses related to our cost-method investments, which include investments in privately held service companies, and research companies. The expense associated with this impairment has been included in other income, net within our condensed consolidated statements of income. We based these impairment losses on our determination that the declines in the fair value of these investments were other-than temporary. We have determined, after the impairment charge, that the fair value of our remaining investments exceed their carrying values.

The following table shows a reconciliation of the changes in our cost-method investments during the six months ended December 31, 2011 (thousands):

|   | Cost-Method Investments |
|---|-------------------------|
| Balance at July 1, 2011                                     | \$ 4,264                |
| Purchases   | 4,796                   |
| Elimination due to acquisition of entity (refer to Note 15) | (2,261)                 |
| Impairment of cost-method investments                       | (2,299)                 |
| Foreign currency translation                                | (24)                    |
| Balance at December 31, 2011                                | \$ 4,476                |

**(7) Goodwill and Other Intangible Assets, net**

Changes in the carrying amount of goodwill for the six months ended December 31, 2011, were as follows (in thousands):

|  |            |
|--|------------|
| Balance at July 1, 2011                  | \$ 235,487 |
| Goodwill on business acquisition         | 51,798     |
| Foreign currency translation adjustments | (26,176)   |
| Balance at December 31, 2011             | \$ 261,109 |

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)**

## (7) Goodwill and Other Intangible Assets, net, Continued

Other intangible assets are comprised of the following as of December 31, 2011, and June 30, 2011 (in thousands):

|  | December 31, 2011 | June 30, 2011 |
|--|-------------------|---------------|
| Developed/core product technology      | \$ 68,412         | \$ 59,293     |
| Accumulated amortization               | (35,628)          | (34,480)      |
| Developed/core product technology, net | 32,784            | 24,813        |
| Trade names                            | 2,697             | 2,577         |
| Accumulated amortization               | (2,122)           | (2,090)       |
| Trade names, net                       | 575               | 487           |
| Non compete agreements                 | 2,312             | 1,928         |
| Accumulated amortization               | (600)             | (333)         |
| Non compete agreements, net            | 1,712             | 1,595         |
| Customer relationships                 | 23,106            | 16,688        |
| Accumulated amortization               | (12,594)          | (11,990)      |
| Customer relationships, net            | 10,512            | 4,698         |
| Patents                                | 55,173            | 54,300        |
| Accumulated amortization               | (39,111)          | (37,982)      |
| Patents, net                           | 16,062            | 16,318        |
| Total other intangibles, net           | \$ 61,645         | \$ 47,911     |

Refer to Note 15 of the condensed consolidated financial statements for further details of acquisitions made during the period.

## (8) Long-Term Debt

Long-term debt at December 31, 2011, and June 30, 2011 consists of the following (in thousands):

|                                       | December 31, 2011 | June 30, 2011 |
|---------------------------------------|-------------------|---------------|
| Current portion of long-term debt     | \$ 1,450          | \$ 163        |
| Non-current portion of long-term debt | 225,000           | 100,000       |
| Total long-term debt                  | \$ 226,450        | \$ 100,163    |

**Credit Facility**

On February 10, 2011, we entered into a credit agreement with lenders, including Union Bank, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, HSBC Bank USA, National Association, as Syndication Agent and Union Bank, N.A., HSBC Bank USA, National Association, Commonwealth Bank of Australia and Wells Fargo Bank, N.A. The credit agreement provides a \$300 million three-year revolving credit facility, with an uncommitted option to increase the credit facility by an additional \$100 million. The credit facility also includes a \$10 million sublimit for letters of credit. The credit facility terminates on February 10, 2014, at which time all unpaid principal and interest under the

## Edgar Filing: RESMED INC - Form 10-Q

loans must be repaid. The outstanding principal amount due under the credit facility will bear interest at a rate equal to, at our option, either (i) LIBOR plus 1.5% to 2.0% (depending on the applicable leverage ratio) or (ii) a base rate, as defined in the credit agreement, plus 0.5% to 1.0% (depending on the applicable leverage ratio). Commitment fees of 0.25% to 0.375% (depending on the applicable leverage ratio) apply on the unused portion of the credit facility. When we executed the credit agreement, we used a portion of the credit facility to repay the outstanding balance under our previously existing revolving credit facility with Union Bank, N.A., which was then terminated.

- 9 -

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)****(8) Long-Term Debt, Continued**

Our obligations under the credit agreement are secured by (a) the corporate stock we hold in our subsidiaries ResMed Corp. and ResMed Motor Technologies Inc. ( ResMed Motor ), and (b) up to 65% of the ownership interests we hold in our subsidiary ResMed EAP Holdings LLC ( ResMed EAP ). Our obligations under the credit agreement are also guaranteed by our subsidiaries ResMed Corp and ResMed Motor. The credit agreement contains customary covenants, including certain financial covenants and an obligation that we maintain certain financial ratios, including a maximum ratio of Funded Debt to EBITDA (each as defined in the credit agreement), an interest coverage ratio and a maximum amount of annual capital expenditures. The entire principal amount of the credit facility and any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs. Events of default include failure to make payments when due, a default in the performance of any covenants in the credit agreement or related documents or certain changes of control of us or our subsidiaries ResMed Corp., ResMed Motor, ResMed Limited, ResMed Holdings Ltd/LLC or ResMed EAP.

At December 31, 2011 we were in compliance with our debt covenants and there was \$225.0 million outstanding under the credit agreement.

**Assumed External Debt**

As part of our acquisition of Gruendler GmbH on August 1, 2011, detailed in Note 15, we assumed debt of 4.7 million Euros. The debt comprises a number of loan agreements of varying terms with financial institutions and venture capital financiers. We repaid 3.7 million Euros during the six months ended December 31, 2011 and expect to settle the remaining outstanding loans within the next six months. Accordingly, all these loans have been treated as current liabilities in our condensed consolidated balance sheets. At December 31, 2011, there was 1.0 million Euros outstanding in respect of these loans.

**(9) Product Warranties**

Changes in the liability for warranty costs, which is included in accrued expenses in our condensed consolidated balance sheets, for the six months ended December 31, 2011 and 2010 are as follows (in thousands):

|  | Six months ended December 31, |           |
|--|-------------------------------|-----------|
|  | 2011                          | 2010      |
| Balance at the beginning of the period   | \$ 19,032                     | \$ 11,507 |
| Warranty accruals for the period         | 8,211                         | 5,714     |
| Warranty costs incurred for the period   | (6,349)                       | (5,632)   |
| Foreign currency translation adjustments | (1,219)                       | 2,336     |
| Balance at the end of the period         | \$ 19,675                     | \$ 13,925 |

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)****(10) Stock-Based Employee Compensation**

We measure the compensation expense of all stock-based awards at fair value on the grant date. We estimate the fair value of stock options and purchase rights granted under the employee stock purchase plan (the ESPP) using Black-Scholes valuation model. The fair value of restricted stock units is equal to the market value of the underlying shares as determined at the grant date. We recognize the fair value as compensation expense using the straight-line method over the service period for awards expected to vest.

We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP assuming no dividends and using the following assumptions:

|  | Three months ended<br>December 31, |          | Six months ended<br>December 31, |          |
|--|------------------------------------|----------|----------------------------------|----------|
|  | 2011                               | 2010     | 2011                             | 2010     |
| Stock options:                           |                                    |          |                                  |          |
| Weighted average grant date fair value   | \$ 8.89                            | \$ 10.32 | \$ 8.90                          | \$ 10.30 |
| Weighted average risk-free interest rate | 1.0%                               | 1.3%     | 1.0%                             | 1.3%     |
| Expected option life in years            | 5.3                                | 5.3      | 5.3                              | 5.0 5.3  |
| Expected volatility                      | 34%                                | 31%      | 31 34%                           | 31 32%   |
| ESPP purchase rights:                    |                                    |          |                                  |          |
| Weighted average risk-free interest rate | 0.1%                               | 0.2%     | 0.1%                             | 0.2%     |
| Expected option life in years            | 6 months                           | 6 months | 6 months                         | 6 months |
| Expected volatility                      | 24 40%                             | 26 29%   | 24 40%                           | 26 29%   |

**(11) Stockholders' Equity**

**Common Stock.** On August 24, 2011, our board of directors approved a new share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of ResMed Inc. common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant. This program canceled and replaced our previous share repurchase program authorized on May 27, 2009 pursuant to which we had repurchased 9,952,274 shares. These were in addition to the 6,622,907 shares repurchased under an earlier program authorized on June 6, 2002. The new program authorizes us to purchase in addition to the shares we repurchased under our previous programs. There is no expiration date for this program. All share repurchases since August 24, 2011 have been executed in accordance with this program.

During the three and six months ended December 31, 2011, we repurchased 4.1 million and 8.5 million shares, respectively, at a cost of \$110.5 million and \$235.2 million, respectively. At December 31, 2011, we have repurchased a total of 22.6 million shares at a cost of \$739.8 million. Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. At December 31, 2011, 14.0 million additional shares can be repurchased under the approved share repurchase program.

**Preferred Stock.** In April 1997, the Board of Directors authorized 2,000,000 shares of \$0.01 par value preferred stock. No such shares were issued or outstanding at December 31, 2011 and June 30, 2011.





**Table of Contents**

PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)**

(11) Stockholders' Equity, Continued

**Stock Options and Restricted Stock Units.** We have granted stock options and restricted stock units to personnel, including officers and directors, in accordance with the ResMed Inc. 2009 Incentive Award Plan (the "2009 Plan"). These options and restricted stock units have expiration dates of seven years from the date of grant and vest over one or four years. We have granted the options with an exercise price equal to the market value as determined at the date of grant.

The maximum number of shares of our common stock authorized for issuance under the 2009 Plan is 35,475,000. The number of securities remaining available for future issuance under the 2009 Plan at December 31, 2011 is 14,251,060. The number of shares of our common stock available for issuance under the 2009 Plan will be reduced by (i) two (2.0) shares for each one share of common stock delivered in settlement of any full-value award, which is any award other than a stock option, stock appreciation right or other award for which the holder pays the intrinsic value and (ii) one share for each share of common stock delivered in settlement of all other awards. The maximum number of shares, which may be subject to awards granted under the 2009 Plan to any individual during any calendar year, may not exceed 3 million shares of our common stock (except in a participant's initial year of hiring up to 4.5 million shares of our common stock may be granted).

At December 31, 2011, there was \$79.8 million in unrecognized compensation costs related to unvested stock-based compensation arrangements. This is expected to be recognized over a weighted average period of 3.1 years. The aggregate intrinsic value of the stock-based compensation arrangements outstanding and exercisable at December 31, 2011 was \$130.1 million and \$62.7 million, respectively. The aggregate intrinsic value of the options exercised during the six months ended December 31, 2011 and 2010, was \$12.0 million and \$40.1 million, respectively.

The following table summarizes option activity during the six months ended December 31, 2011:

|   |                    | Weighted Average | Weighted Average                |
|---|--------------------|------------------|---------------------------------|
|   | Options            | Exercise Price   | Remaining Term to Vest in Years |
| Outstanding at beginning of period      | 12,230,684         | \$ 19.24         | 3.80 years                      |
| Granted                                 | 758,515            | 27.64            |                                 |
| Exercised                               | (1,037,965)        | 18.00            |                                 |
| Forfeited                               | (238,275)          | 23.09            |                                 |
| Outstanding at end of period            | 11,712,959         | \$ 19.82         | 3.55 years                      |
| Exercise price range of granted options | \$ 27.58 - \$30.18 |                  |                                 |
| Options exercisable at end of period    | 8,734,299          | \$ 18.36         |                                 |

The following table summarizes the activity of restricted stock units during the six months ended December 31, 2011:

|                                    |                        | Weighted Average      | Weighted Average Remaining |
|------------------------------------|------------------------|-----------------------|----------------------------|
|                                    | Restricted Stock Units | Grant-Date Fair Value | Term to Vest in Years      |
| Outstanding at beginning of period | 1,635,686              | \$ 30.16              | 1.73 years                 |

Edgar Filing: RESMED INC - Form 10-Q

|                              |           |    |       |            |
|------------------------------|-----------|----|-------|------------|
| Granted                      | 1,137,481 |    | 27.85 |            |
| Vested                       | (406,126) |    | 29.71 |            |
| Forfeited                    | (116,710) |    | 29.61 |            |
| Outstanding at end of period | 2,250,331 | \$ | 29.11 | 2.04 years |

- 12 -

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)**

(11) Stockholders' Equity, Continued

**Employee Stock Purchase Plan (the ESPP).** The ESPP was approved at the annual meeting of our stockholders on November 18, 2009, as an amendment to the previously approved employee stock purchase plan. Under the ESPP, we offer participants the right to purchase shares of our common stock at a discount during successive offering periods. Each offering period under the ESPP will be for a period of time determined by the board of directors' compensation committee of no less than 3 months and no more than 27 months. The purchase price for our common stock under the ESPP will be the lower of 85% of the fair market value of our common stock on the date of grant or 85% of the fair market value of our common stock on the date of purchase. An individual participant cannot subscribe for more than \$25,000 in common stock during any calendar year. At December 31, 2011, the number of shares remaining available for future issuance under the ESPP is 615,000. During the six months ended December 31, 2011, we recognized \$1.2 million of stock-based compensation expense associated with the ESPP.

(12) Derivative Instruments and Hedging Activities

We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have significant foreign currency exposure through both our Australian and Singaporean manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed three years. The goal of this hedging program is to economically manage the financial impact of foreign currency exposures denominated in Euros, Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments.

We do not designate these foreign currency contracts as hedges. We have determined our hedge program to be a non-effective hedge as defined under the FASB issued authoritative guidance. All movements in the fair value of the foreign currency instruments are recorded within other income, net in our consolidated statements of income. We do not enter into financial instruments for trading or speculative purposes.

We held foreign currency instruments with notional amounts totaling \$377.0 million and \$309.9 million at December 31, 2011 and June 30, 2011, respectively, to hedge foreign currency fluctuations. These contracts mature at various dates prior to December 31, 2014.

The fair value and effect of derivative instruments on our condensed consolidated financial statements were as follows (in thousands):

| Derivatives Not Designated as Hedging Instruments | Asset                                    |                                    | Location of gain<br>recognized in Income | Gain recognized in<br>Income<br>Six Months Ended<br>December 31, 2011 |
|---|--|------------------------------------|--|---|
|   | Derivatives<br>Balance Sheet<br>Location | December 31,<br>2011<br>Fair Value |  |   |
| Foreign Exchange Contracts                        | Other Assets                             | \$14,861                           | Other Income                             | \$11,709  |

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)**

## (12) Derivative Instruments and Hedging Activities, Continued

We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments. The credit exposure of foreign currency derivatives at December 31, 2011 and June 30, 2011 was \$14.9 million and \$14.8 million, respectively, which represents the positive fair value of our foreign currency derivatives. These values are included in the current and non-current balances of other assets on the condensed consolidated balance sheets. We minimize counterparty credit risk by entering into derivative transactions with major financial institutions and, as such, we do not expect material losses as a result of default by our counterparties.

## (13) Fair Value Measurements

In determining the fair value measurements of our financial assets and liabilities, we consider the principal and most advantageous market in which we transact and consider assumptions that market participants would use when pricing the financial asset or liability. We maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

The hierarchies of inputs are as follows:

Level 1: Input prices quoted in an active market for identical financial assets or liabilities;

Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data; and

Level 3: Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable nor supported by an active market.

The following table summarizes our financial assets and liabilities, as at December 31, 2011, using the valuation input hierarchy (in thousands):

|                           | Level 1    | Level 2   | Level 3 | Total      |
|---------------------------|------------|-----------|---------|------------|
| Cash and cash equivalents | \$ 723,233 | \$ 0      | \$ 0    | \$ 723,233 |
| Foreign currency options  | 0          | 14,861    | 0       | 14,861     |
|                           | \$ 723,233 | \$ 14,861 | \$ 0    | \$ 738,094 |

We determine the fair value of our financial assets as follows:

Cash and cash equivalents The valuation used for our cash and other money market funds are derived from quoted market prices due to their short term nature and there is an active market for these financial instruments.

## Edgar Filing: RESMED INC - Form 10-Q

Foreign currency options These financial instruments are valued using third party valuation models based on market observable inputs, including interest rate curves, on market spot currency prices, volatilities and credit risk.

We did not have any significant non-financial assets or liabilities measured at fair value on December 31, 2011 or June 30, 2011.

- 14 -

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)**

## (14) Legal Actions and Contingencies

**Litigation**

In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our condensed consolidated financial statements taken as a whole.

In February 2007, the University of Sydney commenced legal action in the Federal Court of Australia against us, claiming breach of a license agreement and infringement of certain intellectual property. The claim has been amended to include an allegation of breach of confidentiality. The university is seeking various types of relief, including an injunction against manufacturing, supplying, offering for sale, selling or exporting certain mask devices, payment of license fees, damages or an account of profits, interest, costs and declaration of a constructive trust over and assignment of certain intellectual property. In October 2007, we filed a defense denying the university's claim, as well as a cross-claim against the university seeking an order for rectification of the contract and alleging the university violated the Australian Trade Practices Act. The matter is ongoing. Given the inherent uncertainty and unpredictability of litigation and due to the status of this legal action, no range of loss or possible loss can be reasonably estimated at this time. However, we do not expect the outcome of this matter to have a material adverse effect on our condensed consolidated financial statements when taken as a whole.

**Contingent Obligations Under Recourse Provisions**

We use independent leasing companies for the purpose of providing finance to certain customers for the purchase of our products. In some cases, we are contingently liable to the leasing companies in the event of a customer default, within certain limits, for unpaid installment receivables transferred to the leasing companies. The gross amount of receivables sold under these arrangements for the six months ended December 31, 2011 amounted to \$6.1 million. The maximum potential amount of contingent liability under these arrangements at December 31, 2011 was \$4.5 million. The recourse liability we recognized at December 31, 2011, in relation to these arrangements was \$0.6 million.

## (15) Acquisitions of Businesses

On July 5, 2011 we acquired the remaining 87% of the outstanding shares of BiancaMed Ltd. ( BiancaMed ), an Irish medical technology company, that has developed and is marketing a convenient, non-contact device to monitor sleep and breathing in the home and hospital. We previously held 13% of the outstanding shares of BiancaMed which was re-measured to its acquisition-date fair value of \$4.3 million based on the difference between the fair value of 100% of BiancaMed's shares less the fair value of the consideration transferred, excluding any control premium. As a result we recognized a gain of \$2.1 million in Other Income during the six months ended December 31, 2011. The acquisition has been accounted for as a business combination using purchase accounting and is included in our consolidated financial statements from July 5, 2011. The acquisition is not considered a material business combination and was funded through cash on-hand. We have not incurred any material acquisition related costs.

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements****(Unaudited)**

## (15) Acquisitions of Businesses, Continued

On August 1, 2011 we acquired 100% of the outstanding shares of Gruendler GmbH, a developer and manufacturer of medical humidification products. These humidifiers can be used with a wide range of ventilators, from neonatal and pediatric, to non-invasive pressure support, to those used in the intensive care unit. Under the purchase agreement, we may also be required to make additional future payments of up to 5.5 million Euros based on the achievement of certain performance milestones following the acquisition. The acquisition has been accounted for as a business combination using purchase accounting and is included in our consolidated financial statements from August 1, 2011. The acquisition is not considered a material business combination and was funded through cash on-hand. We have not incurred any material acquisition related costs.

The cost of the acquisitions has been allocated to the assets acquired and liabilities assumed based on estimates of their respective fair values at the date of acquisition. We completed the purchase price allocations in the quarter ending December 31, 2011 and there were no material modifications from the preliminary purchase price allocation. The goodwill recognized as part of these acquisitions mainly represents the synergies that are unique to our combined businesses and the potential for new products and services to be developed in the future.

The following table summarizes the aggregated purchase price allocation of the assets acquired and liabilities assumed at the date of acquisitions based on an independent appraisal and internal studies (in thousands):

|  | Purchase Price Allocation |
|--|---------------------------|
| Cash   | \$ 4,136                  |
| Accounts receivable  | 352                       |
| Inventory  | 1,249                     |
| Other assets   | 1,030                     |
| Property, plant & equipment  | 3,312                     |
| Developed technology (useful life of 8 years)  | 16,039                    |
| Customer relationships (useful life of 3-5 years)  | 2,205                     |
| Trade name (useful life of 2-3 years)  | 461                       |
| Goodwill (non-amortizing, non-tax deductible)  | 51,798                    |
| Total assets acquired  | \$ 80,582                 |
| Current liabilities, primarily consisting of accounts payable, accrued expenses, debt and deferred tax liabilities | (8,502)                   |
| Non-current liabilities, primarily consisting of deferred tax liabilities  | (3,404)                   |
| Net assets acquired  | \$ 68,676                 |

## (16) Subsequent Events

On January 25, 2012, we entered into a first amendment to the existing credit agreement, between us, as borrower, and lenders, Union Bank, N.A.; HSBC Bank USA, National Association; Commonwealth Bank of Australia and Wells Fargo Bank, N.A. The amendment increases, from \$300 million to \$400 million, the maximum principal amount that can be borrowed on a revolving basis under the credit agreement, subject to customary conditions.





---

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES**

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations  
Special Note Regarding Forward-Looking Statements**

This report contains or may contain certain forward-looking statements and information that are based on the beliefs of our management as well as estimates and assumptions made by, and information currently available to, our management. All statements other than statements regarding historical facts are forward-looking statements. The words believe, expect, anticipate, will continue, will, estimate, plan, future and other similar expressions, and negative statements of such expressions, generally identify forward-looking statements, including, in particular, statements regarding the development and approval of new products and product applications, market expansion, pending litigation and the development of new markets for our products, such as cardiovascular and stroke markets. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on these forward-looking statements. Such forward-looking statements reflect the views of our management at the time such statements are made and are subject to a number of risks, uncertainties, estimates and assumptions, including, without limitation, and in addition to those identified in the text surrounding such statements, those identified in our annual report on Form 10-K for the fiscal year ended June 30, 2011 and elsewhere in this report.

In addition, important factors to consider in evaluating such forward-looking statements include changes or developments in healthcare reform, social, economic, market, legal or regulatory circumstances, changes in our business or growth strategy or an inability to execute our strategy due to changes in our industry or the economy generally, the emergence of new or growing competitors, the actions or omissions of third parties, including suppliers, customers, competitors and governmental authorities and various other factors. Should any one or more of these risks or uncertainties materialize, or underlying estimates or assumptions prove incorrect, actual results may vary significantly from those expressed in such forward-looking statements, and there can be no assurance that the forward-looking statements contained in this report will in fact occur.

Before deciding to purchase, hold or sell our common stock, you should carefully consider the risks described in our annual report on Form 10-K, in addition to the other cautionary statements and risks described elsewhere in this report and in our other filings with the SEC, including our subsequent reports on Forms 10-Q and 8-K. These risks and uncertainties are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business. If any of these known or unknown risks or uncertainties actually occurs with material adverse effects on us, our business, financial condition and results of operations could be seriously harmed. In that event, the market price for our common stock will likely decline and you may lose all or part of your investment.

---

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES**

**Management's Discussion and Analysis of Financial Condition and Results of Operations**

**Overview**

The following is an overview of our results of operations for the three and six months ended December 31, 2011. Management's discussion and analysis of financial condition and results of operations is intended to help the reader understand the results of operations and financial condition of ResMed Inc. Management's discussion and analysis is provided as a supplement to, and should be read in conjunction with selected financial data and condensed consolidated financial statements and notes, included herein.

We are a leading developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing ( SDB ) and other respiratory disorders. During the three and six months ended December 31, 2011, we continued our efforts to build awareness of the consequences of untreated SDB, and to grow our business in this market. In our efforts, we have attempted to raise awareness through market and clinical initiatives highlighting the relationship between sleep-disordered breathing/obstructive sleep apnea and co-morbidities, such as cardiac disease, diabetes, hypertension and obesity, as well as the dangers of sleep apnea with regards to occupational health and safety, especially in the transport industry.

We are committed to ongoing investment in research and development and product enhancements. During the three and six months ended December 31, 2011, we invested \$27.2 million and \$53.4 million, respectively, on research and development activities. Since the development of continuous positive airway pressure ( CPAP ) therapy, we have developed a number of innovative products for SDB and other respiratory disorders including airflow generators, diagnostic products, mask systems, headgear and other accessories. Our new product release schedule remains active across both our mask and flow generator categories. We have recently introduced the Stellar ventilation device, the S9 VPAP series of bilevel devices and the Mirage FX mask. We are taking steps to increase awareness of the health dangers of sleep-disordered breathing by sponsoring educational programs targeted at the primary care physician community. We believe these efforts should further increase awareness of both doctors and patients about the relationship between sleep-disordered breathing, obstructive sleep apnea and co-morbidities such as cardiac disease, diabetes, hypertension and obesity. We believe these efforts should also support our efforts to inform the community of the dangers of sleep apnea in occupational health and safety, especially in the transport industry.

During the three months ended December 31, 2011, our net revenue increased by 9% when compared to the three months ended December 31, 2010. Gross margin was 59.7% for the three months ended December 31, 2011 compared to 60.8% for the three months ended December 31, 2010. Diluted earnings per share for the three months ended December 31, 2011 increased to \$0.42 per share, up from \$0.37 per share in the three months ended December 31, 2010.

At December 31, 2011, our cash and cash equivalents totaled \$723.2 million, our total assets were \$2.0 billion and our stockholders' equity was \$1.6 billion.

In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a constant currency basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollars measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations****Net Revenue**

Net revenue increased for the three months ended December 31, 2011 to \$332.7 million compared to \$306.0 million for the three months ended December 31, 2010, an increase of \$26.7 million or 9%. The increase in net revenue is primarily attributable to an increase in unit sales of our S9 autaset and bilevel flow generators, masks and accessories. Movements in international currencies against the U.S. dollar positively impacted revenues by approximately \$0.7 million during the three months ended December 31, 2011. Excluding the impact of foreign currency movements, net revenue for the three months ended December 31, 2011 increased by 9% compared to the three months ended December 31, 2010.

Net revenue in North and Latin America increased for the three months ended December 31, 2011 to \$182.5 million from \$163.2 million for the three months ended December 31, 2010, an increase of 12%. We believe this increase predominantly reflects growth in the overall sleep-disordered breathing market and growth generated from our recent product releases including the S9 bilevel flow generators and the Quattro FX and Mirage FX masks. Net international revenue, which includes all markets outside North and Latin America, for the three months ended December 31, 2011, increased to \$150.2 million from \$142.8 million for the three months ended December 31, 2010, an increase of 5%. Movements in international currencies against the U.S. dollar positively impacted international revenues by approximately \$0.7 million during the three months ended December 31, 2011. Excluding the impact of movements in international currencies, international sales grew by 5% compared to the three months ended December 31, 2010. We believe this increase in sales outside North and Latin America predominantly reflects growth in the overall sleep-disordered breathing market and growth generated from our recent product releases including the S9 bilevel flow generators and the Quattro FX and Mirage FX masks.

Net revenue from the sales of flow generators, including humidifiers, for the three months ended December 31, 2011 totaled \$180.6 million, an increase of 3% compared to the three months ended December 31, 2010 of \$175.4 million, including increases of 4% in North and Latin America and 2% internationally. Net revenue from the sales of masks and other accessories for the three months ended December 31, 2011 totaled \$152.1 million, an increase of 16% compared to the three months ended December 31, 2010 of \$130.6 million, including increases of 19% in North and Latin America and 12% internationally. Excluding the impact of favorable currency movements, international revenue increased by 2% and 11% for flow generators and masks and other accessories, respectively, for the three months ended December 31, 2011 compared to the three months ended December 31, 2010. We believe these increases primarily reflect growth in the overall sleep-disordered breathing market and contributions from new products.

The following table summarizes the percentage movements in our net revenue for the three months ended December 31, 2011 compared to the three months ended December 31, 2010:

|                             | North and<br>Latin America | International | Total | International<br>(Constant<br>Currency)<br>* | Total<br>(Constant<br>Currency) |
|-----------------------------|----------------------------|---------------|-------|--|---------------------------------|
| Flow generators             | 4%                         | 2%            | 3%    | 2%   | 3%                              |
| Masks and other accessories | 19%                        | 12%           | 16%   | 11%  | 16%                             |
| Total                       | 12%                        | 5%            | 9%    | 5%   | 9%                              |

\* Constant currency numbers exclude the impact of movements in international currencies.

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations****Net Revenue, continued**

Net revenue for the six months ended December 31, 2011, was \$647.5 million as compared to \$588.0 million for the six months ended December 31, 2010, an increase of 10%. For the six months ended December 31, 2011, revenue from sales of flow generators increased by 4% compared to the six months ended December 31, 2010, comprising a 1% increase in North and Latin America and a 7% increase internationally. Revenue from sales of mask systems, motors and other accessories increased by 18%, comprising a 19% increase in North and Latin America and a 16% increase internationally, for the six months ended December 31, 2011 compared to the six months ended December 31, 2010. Movement in international currencies against the U.S. dollar positively impacted net revenue by approximately \$11.2 million during the six months ended December 31, 2011. Excluding the impact of favorable currency movements, total revenue for the six months ended December 31, 2011 increased by 8% compared to the six months ended December 31, 2010. We believe these increases primarily reflect growth in the overall sleep-disordered breathing market, and strong sales from our new products.

The following table summarizes the percentage movements in our net revenue for the six months ended December 31, 2011 compared to the six months ended December 31, 2010:

|                                     | North and<br>Latin America | International | Total | International<br>(Constant<br>Currency)<br>* | Total<br>(Constant<br>Currency) * |
|-------------------------------------|----------------------------|---------------|-------|--|-----------------------------------|
| Flow generators                     | 1%                         | 7%            | 4%    | 3%   | 2%                                |
| Masks, motors and other accessories | 19%                        | 16%           | 18%   | 11%  | 16%                               |
| Total                               | 10%                        | 10%           | 10%   | 6%   | 8%                                |

\* Constant currency numbers exclude the impact of movements in international currencies.

**Gross Profit**

Gross profit increased for the three months ended December 31, 2011 to \$198.7 million from \$186.0 million for the three months ended December 31, 2010, an increase of \$12.7 million or 7%. Gross profit as a percentage of net revenue for the three months ended December 31, 2011 decreased to 59.7% from 60.8% for the three months ended December 31, 2010.

Gross profit increased for the six months ended December 31, 2011 to \$383.8 million from \$360.0 million for the six months ended December 31, 2010, an increase of \$23.8 million or 7%. Gross profit as a percentage of net revenue for the six months ended December 31, 2011 was 59.3% compared to 61.2% for the six months ended December 31, 2010.

The decline in gross margins for the three and six months ended December 31, 2011 is primarily due to unfavorable movements in foreign currencies, predominantly the appreciation of the Australian dollar against the U.S. dollar as the majority of our manufacturing labor and overhead is denominated in Australian dollars, and declines in our average selling prices. These negative impacts were partially offset by positive impacts associated with a favorable change in product mix, as sales of our higher margin products represented a higher proportion of our sales, and cost savings attributable to manufacturing and supply chain improvements.



---

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES**

**Management's Discussion and Analysis of Financial Condition and Results of Operations**

**Selling, General and Administrative Expenses**

Selling, general and administrative expenses increased for the three months ended December 31, 2011 to \$100.6 million from \$91.6 million for the three months ended December 31, 2010, an increase of \$9.0 million or 10%. Selling, general and administrative expenses, as a percentage of net revenue, were 30.2% for the three months ended December 31, 2011 compared to 29.9% for the three months ended December 31, 2010.

Selling, general and administrative expenses increased for the six months ended December 31, 2011 to \$194.8 million from \$176.4 million for the six months ended December 31, 2010, an increase of \$18.4 million or 10%. Selling, general and administrative expenses, as a percentage of net revenue, were 30.1% for the six months ended December 31, 2011 compared to 30.0% for the six months ended December 31, 2010.

The increase in selling, general and administrative expenses was primarily due to an increase in the number of sales and administrative personnel to support our growth and other expenses related to the increase in our sales. The increase in selling, general and administrative expenses was also impacted by the net appreciation of international currencies against the U.S. dollar, which increased our expenses by approximately \$0.5 million and \$5.9 million for the three and six months ended December 31, 2011, respectively, as reported in U.S. dollars. As a percentage of net revenue, we expect our future selling, general and administrative expense to be approximately 30%.

**Research and Development Expenses**

Research and development expenses increased for the three months ended December 31, 2011 to \$27.2 million from \$22.0 million for the three months ended December 31, 2010, an increase of \$5.2 million or 24%. Research and development expenses, as a percentage of net revenue, were 8.2% for the three months ended December 31, 2011, compared to 7.2% for the three months ended December 31, 2010.

Research and development expenses increased for the six months ended December 31, 2011 to \$53.4 million from \$41.7 million for the six months ended December 31, 2010, an increase of \$11.7 million or 28%. Research and development expenses, as a percentage of net revenue, were 8.3%, for the six months ended December 31, 2011 compared to 7.1% for the six months ended December 31, 2010.

The increase in research and development expenses was primarily due to an increase in the number of research and development personnel, consulting and contractor expenses and an increase in materials and tooling costs incurred to facilitate development of new products. The increase in research and development expenses was also due to the net appreciation of the Australian dollar against the U.S. dollar, which increased our expenses by approximately \$0.6 million and \$3.6 million for the three and six months ended December 31, 2011, respectively, as reported in U.S. dollars. As a percentage of net revenue, we expect our future research and development expense to continue to be approximately 8%.

---

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations****Amortization of Acquired Intangible Assets**

Amortization of acquired intangible assets for the three and six months ended December 31, 2011 totaled \$3.7 million and \$7.5 million, respectively, as compared to \$2.6 million and \$4.6 million for the three and six months ended December 31, 2010, respectively. The increase in amortization expense is mainly attributable to our recent acquisitions.

**Donations to Foundation**

For the three and six months ended December 31, 2011, we did not make a donation to the ResMed Foundation (the Foundation). The Foundation was established primarily to promote research into the deleterious medical consequences of untreated sleep-disordered breathing and to increase public and physician awareness of the importance of sleep and respiratory health throughout the world. For the three and six months ended December 31, 2010, we donated a total of \$Nil and \$1.0 million, respectively, to the ResMed Foundation.

**Other Income, Net**

Other income, net for the three and six months ended December 31, 2011 was \$15.7 million and \$21.3 million, respectively, compared to \$9.0 million and \$19.2 million, respectively, for the three and six months ended December 31, 2010. The increase in other income, net, during the three and six months ended December 31, 2011, was predominantly due to gains on foreign currency and hedging transactions. The increase was also, due to the increase in interest income as a result of higher cash balances.

**Income Taxes**

Our effective income tax rate of approximately 24.2% for the three months ended December 31, 2011 was lower than our effective income tax rate of approximately 25.9% for the three months ended December 31, 2010. Our effective income tax rate of approximately 24.1% for the six months ended December 31, 2011 was lower than our effective tax rate of 25.9% for the six months ended December 31, 2010. The lower tax rate was primarily due to a change in the geographic mix of our taxable income.

We continue to benefit from the Australian and Singapore corporate tax rates and certain Australian research and development tax benefits because we generate the majority of our taxable income in Australia.

**Net Income**

Our net income for the three months ended December 31, 2011 was \$62.9 million or \$0.42 per diluted share compared to net income of \$58.5 million or \$0.37 per diluted share for the three months ended December 31, 2010, an increase of 8% and 14%, respectively, over the three months ended December 31, 2010.

Our net income for the six months ended December 31, 2011 was \$113.4 million or \$0.75 per diluted share compared to net income of \$115.2 million or \$0.73 per diluted share for the six months ended December 31, 2010, a decrease of 2% and an increase of 3%, respectively, over the six months ended December 31, 2010.



**Table of Contents**

PART I FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations****Liquidity and Capital Resources**

As of December 31, 2011 and June 30, 2011, we had cash and cash equivalents of \$723.2 million and \$735.3 million, respectively. Working capital was \$1.0 billion and \$1.1 billion at December 31, 2011 and June 30, 2011, respectively.

As of December 31, 2011 and June 30, 2011, our cash and cash equivalent balances held within the United States amounted to \$51.1 million and \$111.2 million, respectively. Our remaining cash and cash equivalent balances at December 31, 2011 and June 30, 2011, of \$672.1 million and \$624.1 million, respectively, were held by our non-U.S. subsidiaries, indefinitely invested outside the United States. Our cash and cash equivalent balances are held at highly rated financial institutions. Should we repatriate our cash and cash equivalent balances held outside the U.S., we would have to adjust the income tax provision in the period any such repatriation were to occur.

Inventories at December 31, 2011 were \$184.4 million, a decrease of \$30.5 million or 14% over the December 31, 2010 balance of \$214.9 million. The decrease in inventories mainly reflects a general improvement in inventory management compared to December 31, 2010.

Accounts receivable at December 31, 2011 were \$238.8 million, a decrease of \$12.3 million or 5% over the December 31, 2010 accounts receivable balance of \$251.1 million. Accounts receivable days outstanding of 63 days at December 31, 2011 decreased by 4 days compared to the 67 days at December 31, 2010. Our allowance for doubtful accounts as a percentage of total accounts receivable at December 31, 2011 and June 30, 2011 was 3.4% and 4.0%, respectively. The decrease in the allowance for doubtful accounts as a percentage of total accounts receivable mainly reflects the write-off of certain bad debts against a specific provision. To date we have not experienced any significant decline in the credit quality of our customers and it remains broadly consistent with our past experience.

At December 31, 2011, no capital lease obligations exist. Details of our contractual obligations at December 31, 2011 are as follows:

| In \$000 s           | Total      | Payments Due in the Year Ending December 31, |          |            |          |          | Thereafter |
|----------------------|------------|--|----------|------------|----------|----------|------------|
|                      |            | 2012   | 2013     | 2014       | 2015     | 2016     |            |
| Long-Term Debt       | \$ 226,450 | \$ 1,450                                     | \$ 0     | \$ 225,000 | \$ 0     | \$ 0     | \$ 0       |
| Operating Leases     | 35,420     | 11,888                                       | 9,420    | 7,100      | 3,541    | 2,398    | 1,073      |
| Purchase Obligations | 74,925     | 74,622                                       | 303      | 0          | 0        | 0        | 0          |
| Total <sup>(A)</sup> | \$ 336,795 | \$ 87,960                                    | \$ 9,723 | \$ 232,100 | \$ 3,541 | \$ 2,398 | \$ 1,073   |

(A) The liabilities related to unrecognized tax benefits are not included in the above contractual obligations because the timing cannot be reliably estimated.

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations****Liquidity and Capital Resources, Continued**

Details of other commercial commitments as at December 31, 2011 are as follows:

| In \$000 s                | Amount of Commitment Expiration Per Year Ending December 31, |          |          |          |        |      |            |
|---------------------------|--|----------|----------|----------|--------|------|------------|
|                           | Total  | 2012     | 2013     | 2014     | 2015   | 2016 | Thereafter |
| Standby Letters of Credit | \$ 89  | \$ 54    | \$ 0     | \$ 0     | \$ 0   | \$ 0 | \$ 35      |
| Guarantees                | 8,664  | 4,107    | 832      | 802      | 318    | 0    | 2,605      |
| Other                     | 1,356  | 540      | 408      | 408      | 0      | 0    | 0          |
| Total                     | \$ 10,109  | \$ 4,701 | \$ 1,240 | \$ 1,210 | \$ 318 | \$ 0 | \$ 2,640   |

We use independent leasing companies for the purpose of providing finance to certain customers for the purchase of our products. In some cases, we are contingently liable to the leasing companies in the event of a customer default, within certain limits, for unpaid installment receivables transferred to the leasing companies. The gross amount of receivables sold under these arrangements for the six months ended December 31, 2011 amounted to \$6.1 million. The maximum potential amount of contingent liability under these arrangements at December 31, 2011 was \$4.5 million. The recourse liability we recognized at December 31, 2011, in relation to these leasing arrangements was \$0.6 million.

**Credit Facility**

On February 10, 2011, we entered into a credit agreement with lenders, including Union Bank, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, HSBC Bank USA, National Association, as Syndication Agent and Union Bank, N.A., HSBC Bank USA, National Association, Commonwealth Bank of Australia and Wells Fargo Bank, N.A. The credit agreement provides a \$300 million three-year revolving credit facility, with an uncommitted option to increase the credit facility by an additional \$100 million. The credit facility also includes a \$10 million sublimit for letters of credit. The credit facility terminates on February 10, 2014, at which time all unpaid principal and interest under the loans must be repaid. The outstanding principal amount due under the credit facility will bear interest at a rate equal to, at our option, either (i) LIBOR plus 1.5% to 2.0% (depending on the applicable leverage ratio) or (ii) a base rate, as defined in the credit agreement, plus 0.5% to 1.0% (depending on the applicable leverage ratio). Commitment fees of 0.25% to 0.375% (depending on the applicable leverage ratio) apply on the unused portion of the credit facility.

Our obligations under the credit agreement are secured by (a) the corporate stock we hold in our subsidiaries ResMed Corp. and ResMed Motor Technologies Inc. ( ResMed Motor ), and (b) up to 65% of the ownership interests we hold in our subsidiary ResMed EAP Holdings LLC ( ResMed EAP ). Our obligations under the credit agreement are also guaranteed by our subsidiaries ResMed Corp and ResMed Motor. The credit agreement contains customary covenants, including certain financial covenants and an obligation that we maintain certain financial ratios, including a maximum ratio of Funded Debt to EBITDA (each as defined in the credit agreement), an interest coverage ratio and a maximum amount of annual capital expenditures. The entire principal amount of the credit facility and any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs. Events of default include failure to make payments when due, a default in the performance of any covenants in the credit agreement or related documents or certain changes of control of us or our subsidiaries ResMed Corp., ResMed Motor, ResMed Limited, ResMed Holdings Ltd/LLC or ResMed EAP. At December 31, 2011 there was \$225.0 million outstanding under the credit agreement and we were in compliance with our debt covenants.

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES**

**Management's Discussion and Analysis of Financial Condition and Results of Operations**

**Liquidity and Capital Resources, Continued**

**Acquired External Debt**

As part of our acquisition of Gruendler GmbH on August 1, 2011, detailed in Note 15, we assumed debt of 4.7 million Euros. The debt comprises a number of loan agreements of varying terms with financial institutions and venture capital financiers. We repaid 3.7 million Euros during the six months ended December 31, 2011 and expect to pay off the remaining outstanding loans within the next six months. Accordingly, all these loans have been treated as current liabilities in our condensed consolidated balance sheets. At December 31, 2011, there was 1.0 million Euros outstanding in respect of these loans.

We expect to satisfy all of our short-term liquidity requirements through a combination of cash on hand and cash generated from operations, and the unused portion of our credit facility.

**Acquisitions of Businesses and Business Assets**

During the six months ended December 31, 2011 we acquired BiancaMed Limited and Gruendler GmbH for a total consideration of \$64.5 million. All acquisitions were funded out of our cash on-hand. BiancaMed Ltd. is an Irish medical technology company that has developed and is marketing a convenient, non-contact device to monitor sleep and breathing in the home and hospital. Gruendler GmbH is a developer and manufacturer of medical humidification products that can be used with a wide range of ventilators, from neonatal and pediatric, to non-invasive pressure support, to those used in the intensive care unit. The acquisitions have been accounted for as business combinations using purchase accounting and are included in our consolidated financial statements from the date of the acquisitions. The acquisitions are not considered material business combinations and we have not incurred any material acquisition related costs. Refer to Note 15 of the condensed consolidated financial statements for further details of acquisitions made during the period.

---

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES**

**Management's Discussion and Analysis of Financial Condition and Results of Operations**

**Common Stock**

On August 24, 2011, our board of directors approved a new share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of ResMed Inc. common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant. This program canceled and replaced our previous share repurchase program authorized on May 27, 2009 pursuant to which we had repurchased 9,952,274 shares. These were in addition to the 6,622,907 shares repurchased under an earlier program authorized on June 6, 2002. The new program authorizes us to purchase in addition to the shares we repurchased under our previous programs. There is no expiration date for this program. All share repurchases since August 24, 2011 have been executed in accordance with this program.

During the three and six months ended December 31, 2011, we repurchased 4.1 million and 8.5 million shares, respectively, at a cost of \$110.5 million and \$235.2 million, respectively. At December 31, 2011, we have repurchased a total of 22.6 million shares at a cost of \$739.8 million. Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. At December 31, 2011, 14.0 million additional shares can be repurchased under the approved share repurchase program.

**Critical Accounting Principles and Estimates**

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect our reported amounts of assets and liabilities, revenues and expenses and related disclosures of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, including those related to allowance for doubtful accounts, inventory reserves, warranty obligations, goodwill, potentially impaired assets, intangible assets, income taxes and contingencies.

We state these accounting policies in the notes to the financial statements and at relevant sections in this discussion and analysis. The estimates are based on the information that is currently available to us and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could vary from those estimates under different assumptions or conditions.

For a full discussion of our critical accounting policies, see our Annual Report on Form 10-K for the year ended June 30, 2011.

**Recently Issued Accounting Pronouncements**

See note 2 to the condensed consolidated financial statements for a description of recently issued accounting pronouncements, including the expected dates of adoption and estimated effects on our results of operations, financial positions and cash flows.

**Off-Balance Sheet Arrangements**

Except for operating leases and receivables transferred to leasing companies with certain recourse limits, as of December 31, 2011, we are not involved in any significant off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated by the SEC.

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 3

**RESMED INC. AND SUBSIDIARIES****Item 3. Quantitative and Qualitative Disclosures About Market Risk  
Foreign Currency Market Risk**

Our reporting currency is the U.S. dollar, although the financial statements of our non-U.S. subsidiaries are maintained in their respective local currencies. We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have significant foreign currency exposure through both our Australian and Singapore manufacturing activities and international sales operations. We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The goal of this hedging program is to economically manage the financial impact of foreign currency exposures denominated in Euros and Australian dollars and Singapore dollars. Under this program, increases or decreases in our foreign-currency-denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. We do not enter into financial instruments for trading or speculative purposes. The foreign currency derivatives portfolio is recorded in the consolidated balance sheets at fair value and included in other assets or other liabilities. All movements in the fair value of the foreign currency derivatives are recorded within other income, net, on our consolidated statements of income.

The table below provides information (in U.S. dollars) on our foreign-currency-denominated financial assets by legal entity functional currency as of December 31, 2011 (in thousands):

|   | Australian<br>Dollar<br>(AUD) | U.S.<br>Dollar (USD) | Euro<br>(EUR) | British<br>Pound<br>(GBP) | Swedish<br>Kroner<br>(SEK) | Swiss<br>Franc<br>(CHF) | Canadian<br>Dollar<br>(CAD) |
|---|-------------------------------|----------------------|---------------|---------------------------|----------------------------|-------------------------|-----------------------------|
| <b>AUD Functional Currency Entities:</b>  |                               |                      |               |                           |                            |                         |                             |
| Assets                                    | \$ 0                          | \$ 105,537           | \$ 101,528    | \$ 0                      | \$ 203                     | \$ 0                    | \$ 0                        |
| Liability                                 | 0                             | (97,715)             | (73,456)      | (692)                     | (19)                       | (2,687)                 | 0                           |
| Net Total                                 | 0                             | 7,822                | 28,072        | (692)                     | 184                        | (2,687)                 | 0                           |
| <b>USD Functional Currency Entities:</b>  |                               |                      |               |                           |                            |                         |                             |
| Assets                                    | 0                             | 0                    | 0             | 0                         | 0                          | 0                       | 8,091                       |
| Liability                                 | 0                             | 0                    | (361)         | 0                         | 0                          | 0                       | 0                           |
| Net Total                                 | 0                             | 0                    | (361)         | 0                         | 0                          | 0                       | 8,091                       |
| <b>EURO Functional Currency Entities:</b> |                               |                      |               |                           |                            |                         |                             |
| Assets                                    | 0                             | 0                    | 0             | 2,042                     | 3,245                      | 1,509                   | 0                           |
| Liability                                 | 0                             | (487)                | 0             | (1,279)                   | (145)                      | (198)                   | 0                           |
| Net Total                                 | 0                             | (487)                | 0             | 763                       | 3,100                      | 1,311                   | 0                           |
| <b>MYR Functional Currency Entities:</b>  |                               |                      |               |                           |                            |                         |                             |
| Assets                                    | 3                             | 50                   | 60            | 0                         | 0                          | 0                       | 0                           |
| Liability                                 | (39)                          | (3,943)              | 0             | 0                         | 0                          | 0                       | 0                           |
| Net Total                                 | (36)                          | (3,893)              | 60            | 0                         | 0                          | 0                       | 0                           |
| <b>SGD Functional Currency Entities:</b>  |                               |                      |               |                           |                            |                         |                             |
| Assets                                    | 2,219                         | 31,954               | 43,325        | 0                         | 244                        | 0                       | 0                           |
| Liability                                 | (5,218)                       | (22,750)             | (44,036)      | (139)                     | 0                          | 0                       | 0                           |
| Net Total                                 | (2,999)                       | 9,204                | (711)         | (139)                     | 244                        | 0                       | 0                           |
| <b>INR Functional Currency Entities:</b>  |                               |                      |               |                           |                            |                         |                             |
| Assets                                    | 1                             | 0                    | 0             | 0                         | 0                          | 0                       | 0                           |
| Liability                                 | 0                             | (2,529)              | (654)         | 0                         | 0                          | 0                       | 0                           |
| Net Total                                 | 1                             | (2,529)              | (654)         | 0                         | 0                          | 0                       | 0                           |

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 3

**RESMED INC. AND SUBSIDIARIES****Quantitative and Qualitative Disclosures About Market Risk****Foreign Currency Market Risk, Continued**

The table below provides information about our foreign currency derivative financial instruments and presents the information in U.S. dollar equivalents. The table summarizes information on instruments and transactions that are sensitive to foreign currency exchange rates, including foreign currency hedges and forward contracts held at December 31, 2011. The table presents the notional amounts and weighted average exchange rates by contractual maturity dates for our foreign currency derivative financial instruments. These notional amounts generally are used to calculate payments to be exchanged under our foreign currency contracts.

(In thousands except exchange rates)

| Foreign Exchange Contracts     | FY 2012             | FY 2013             | FY 2014             | Total               | Fair Value   |               |
|--------------------------------|---------------------|---------------------|---------------------|---------------------|--------------|---------------|
|                                |                     |                     |                     |                     | Assets /     | (Liabilities) |
|                                |                     |                     |                     |                     | Dec 31, 2011 | Jun 30, 2011  |
| <b>Receive AUD/Pay USD</b>     |                     |                     |                     |                     |              |               |
| Contract amount                | \$60,000            | \$60,000            | \$20,000            | \$140,000           | \$6,048      | \$9,551       |
| Ave. contractual exchange rate | AUD 1 = USD 0.9550  | AUD 1 = USD 0.9962  | AUD 1 = USD 1.0596  | AUD 1 = USD 0.9864  |              |               |
| <b>Receive AUD/Pay Euro</b>    |                     |                     |                     |                     |              |               |
| Contract amount                | \$59,620            | \$106,280           | \$38,880            | \$204,780           | \$8,819      | \$5,323       |
| Ave. contractual exchange rate | AUD 1 = Euro 0.7450 | AUD 1 = Euro 0.7467 | AUD 1 = Euro 0.7500 | AUD 1 = Euro 0.7469 |              |               |
| <b>Receive SGD/Pay Euro</b>    |                     |                     |                     |                     |              |               |
| Contract amount                | \$32,400            | 0                   | 0                   | \$32,400            | (\$6)        | 0             |
| Ave. contractual exchange rate | SGD 1 = USD 0.5951  |                     |                     | SGD 1 = USD 0.5951  |              |               |

**Interest Rate Risk**

We are exposed to risk associated with changes in interest rates affecting the return on our cash and cash equivalents, investment securities and debt. At December 31, 2011, we maintained cash and cash equivalents of \$723.2 million containing financial instruments that have original maturities of less than 90 days. These financial instruments are principally comprised of bank term deposits and at call accounts and are invested at both short term fixed interest rates and variable interest rates. At December 31, 2011, we had total long-term debt, including the current portion of those obligations, of \$226.5 million. All of this debt is subject to variable interest rates. A hypothetical 10% change in interest rates during the three months ended December 31, 2011, would not have had a material impact on our pretax income. We have no interest rate hedging agreements.

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 4

**RESMED INC. AND SUBSIDIARIES**

**Item 4. Controls and Procedures**

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our reports pursuant to the Securities Exchange Act of 1934 (the Exchange Act) is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance management necessarily was required to apply its judgment in evaluating the cost benefit relationship of possible controls and procedures.

As required by Rule 13a-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2011.

There has been no change in our internal controls over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

**Table of Contents**

PART II OTHER INFORMATION

Item 1-6

**RESMED INC. AND SUBSIDIARIES****Item 1 Legal Proceedings**

The information required by this Item is incorporated herein by reference to Note 14, Legal Actions and Contingencies, to the unaudited condensed consolidated financial statements under Part I, Item 1 of this report.

**Item 1A Risk Factors**

The discussion of our business and operations should be read together with the risk factors contained in our annual report on Form 10-K for the fiscal year ended June 30, 2011, which was filed with the SEC and describes the various risks and uncertainties to which we are or may become subject. At December 31, 2011, there have been no material changes to the risk factors set forth in our annual report on Form 10-K for the year ended June 30, 2011.

**Item 2 Unregistered Sales of Equity Securities and Use of Proceeds**

Purchases of equity securities. The following table summarizes purchases by us of our common stock during the six months ended December 31, 2011:

| Period                         | Total Number<br>of Shares<br>Purchased | Average Price<br>Paid per Share | Total Number of Shares<br>Purchased as Part of<br>Publicly Announced<br>Plans or Programs<br>(1) | Maximum Number of Shares<br>that May Yet Be<br>Purchased<br>Under the Plans or<br>Programs (1) |
|--------------------------------|--|---------------------------------|--|--|
| July 1 July 31, 2011           | 98,543                                 | \$ 30.84                        | 14,213,273   | 9,566,278  |
| August 1 August 23, 2011       | 2,361,908                              | 28.34                           | 16,575,181   | 7,204,370  |
| New Program Authorization (1)  |  |                                 |  | 20,000,000   |
| August 24 August 31, 2011      | 275,000                                | 29.27                           | 16,850,181   | 19,725,000   |
| September 1 September 30, 2011 | 1,616,024                              | 28.88                           | 18,466,205   | 18,108,976   |
| October 1 October 31, 2011     | 1,066,155                              | 28.77                           | 19,532,360   | 17,042,821   |
| November 1 November 30, 2010   | 1,624,113                              | 26.87                           | 21,156,473   | 15,418,708   |
| December 1 December 31, 2010   | 1,450,000                              | 24.94                           | 22,606,473   | 13,968,708   |
| Total                          | 8,491,743                              | \$ 32.73                        | 22,606,473   | 13,968,708   |

- (1) On August 24, 2011, our board of directors approved a new share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of ResMed Inc. common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant. This program canceled and replaced our previous share repurchase program authorized on May 27, 2009 pursuant to which we had repurchased 9,952,274 shares. These were in addition to the 6,622,907 shares repurchased under an earlier program authorized on June 6, 2002. The new program authorizes us to purchase in addition to the shares we repurchased under our previous programs. There is no expiration date for this program. All share repurchases since August 24, 2011 have been executed in accordance with this program. Since the inception of the share buyback programs, we have repurchased 22,606,473 shares at a total cost of \$739.8 million.

**Item 3 Defaults Upon Senior Securities**

None



**Item 4**    **Removed and Reserved**

**Item 5**    **Other Information**  
None

- 30 -

---

**Table of Contents**

PART II OTHER INFORMATION

Item 1-6

**RESMED INC. AND SUBSIDIARIES**

**Item 6 Exhibits**

Exhibits (numbered in accordance with Item 601 of Regulation S-K)

- 3.1 First Restated Certificate of Incorporation of ResMed Inc. <sup>(1)</sup>
- 3.2 Fourth Amended and Restated Bylaws of ResMed Inc. <sup>(2)</sup>
- 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 <sup>(3)</sup>
- 31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 <sup>(3)</sup>
- 32 Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 <sup>(3)</sup>
- 101 The following financial statements from ResMed Inc.'s Quarterly Report on Form 10-Q for the quarter ended December 31, 2011, filed on February 2, 2012, formatted in XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Income, (iii) Condensed Consolidated Statements of Cash Flows, (iv) the Notes to the Condensed Consolidated Financial Statements.

(1) Incorporated by reference to Exhibit 3.1 to the Registrants' Annual Report on Form 10-K for the Fiscal Year ended June 30, 2007.

(2) Incorporated by reference to Exhibit 3.1 to the Registrants' Current Report on Form 8-K filed on December 14, 2007.

(3) Filed herewith.

**Table of Contents**

PART II OTHER INFORMATION

SIGNATURES

**RESMED INC. AND SUBSIDIARIES**

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

February 2, 2012

ResMed Inc.

**/s/ PETER C. FARRELL**

Peter C. Farrell

Chairman, Chief Executive Officer and President

(Principal Executive Officer)

**/s/ BRETT A. SANDERCOCK**

Brett A. Sandercock

Chief Financial Officer

(Principal Financial Officer)